Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver
Recent advances in molecular biology have made gene therapy for cancer feasible in clinical trials. Although recombinant adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenovirus vectors may be limited by their immunogenicity. It has been shown that neutralizing antibodies against adenoviruses reduce the efficiency of vector readministration. It is of great importance to examine the effects of human sera on adenovirus-mediated gene transfer, because the majority of prospective gene therapy patients are likely to have been exposed to wild-type adenoviruses. In the present study, it was shown that anti-adenovirus antibody-positive human sera with the lowest positive titer substantially inhibit the adenovirus-mediated gene transfer not only in vitro but also in vivo. These results may have important implications for efficacy considerations when adenovirus vectors are employed in the clinical setting.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1998 |
|---|---|
| Erschienen: |
1998 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Anticancer research - 18(1998), 4A vom: 28. Juli, Seite 2345-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuriyama, S [VerfasserIn] |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 01.09.1998 Date Revised 15.11.2012 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM096432691 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM096432691 | ||
| 003 | DE-627 | ||
| 005 | 20231222103836.0 | ||
| 007 | tu | ||
| 008 | 231222s1998 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0322.xml |
| 035 | |a (DE-627)NLM096432691 | ||
| 035 | |a (NLM)9703877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuriyama, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver |
| 264 | 1 | |c 1998 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.1998 | ||
| 500 | |a Date Revised 15.11.2012 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Recent advances in molecular biology have made gene therapy for cancer feasible in clinical trials. Although recombinant adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenovirus vectors may be limited by their immunogenicity. It has been shown that neutralizing antibodies against adenoviruses reduce the efficiency of vector readministration. It is of great importance to examine the effects of human sera on adenovirus-mediated gene transfer, because the majority of prospective gene therapy patients are likely to have been exposed to wild-type adenoviruses. In the present study, it was shown that anti-adenovirus antibody-positive human sera with the lowest positive titer substantially inhibit the adenovirus-mediated gene transfer not only in vitro but also in vivo. These results may have important implications for efficacy considerations when adenovirus vectors are employed in the clinical setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a beta-Galactosidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.23 |2 NLM | |
| 700 | 1 | |a Tominaga, K |e verfasserin |4 aut | |
| 700 | 1 | |a Kikukawa, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nakatani, T |e verfasserin |4 aut | |
| 700 | 1 | |a Tsujinoue, H |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, S |e verfasserin |4 aut | |
| 700 | 1 | |a Toyokawa, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mitoro, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fukui, H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 18(1998), 4A vom: 28. Juli, Seite 2345-51 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:1998 |g number:4A |g day:28 |g month:07 |g pages:2345-51 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 1998 |e 4A |b 28 |c 07 |h 2345-51 | ||